Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 10;9(4):928. doi: 10.3390/cells9040928

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Dependence and reversibility of EC barrier stability in HUVEC and EA.hy926. (A) Resistance following treatment with 3 µM S1PR1 antagonist W146 or 120 µg/mL of anti-S1P antibody Sphingomab, followed by the removal of the added substances. Line plot represents one experiment out of three with black arrows indicating the addition and removal of W146 or Sphingomab at the corresponding time points. (B) Immunofluorescence staining of VE-cadherin in HUVEC after addition of 3 µM S1PR1 antagonist W146, followed by removal of the added substance. Representative images from one out of three individual experiments are shown. Pictures were taken 6 h after addition of W146 and 12 h following removal of W146.